{"controller"=>"catalog", "action"=>"show", "id"=>"249791464"}
  • EN
  • DA

Danish NationalResearch Database

  • Search Publications & Researchers
  • Open Access Indicator
  • Publications
  • Researchers
Example Finds records
water{} containing the word "water".
water supplies"{}" containing the phrase "water supplies".
author:"Doe, John"author:"{}" containing the prase "Doe, John" in the author field.
title:IEEEtitle:{} containing the word "IEEE" in the title field.
Need more help? Advanced search tutorial
  • Selected (0)
  • History

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

    • Save to Mendeley
    • Export to BibTeX
    • Export to RIS
    • Email citation
Authors:
  • White, William B ;
    Close
    unknown
  • Cannon, Christopher P ;
    Close
    unknown
  • Heller, Simon R ;
    Close
    unknown
  • Nissen, Steven E ;
    Close
    unknown
  • Bergenstal, Richard M ;
    Close
    unknown
  • Bakris, George L ;
    Close
    unknown
  • Perez, Alfonso T ;
    Close
    unknown
  • Fleck, Penny R ;
    Close
    unknown
  • Mehta, Cyrus R ;
    Close
    unknown
  • Kupfer, Stuart ;
    Close
    unknown
  • Wilson, Craig ;
    Close
    unknown
  • Cushman, William C ;
    Close
    unknown
  • Zannad, Faiez ;
    Close
    unknown
  • Investigators, EXAMINE ;
    Close
    unknown
  • Perrild, Hans Jørgen Duckert
    Close
    Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet
DOI:
10.1056/NEJMoa1305889
Abstract:
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Type:
Journal article
Language:
English
Published in:
New England Journal of Medicine, 2013, Vol 369, Issue 14, p. 1327-1335
Keywords:
Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Hemoglobin A, Glycosylated; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Piperidines; Uracil; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Main Research Area:
Medical science
Publication Status:
Published
Review type:
Peer Review
Submission year:
2013
Scientific Level:
Scientific
ID:
249791464

Full text access

  • Doi Get publisher edition via DOI resolver
Checking for on-site access...

On-site access

At institutions

  • Copenhagen university.en
  • Capital region

Metrics

Feedback

Sitemap

  • Search
    • Statistics
    • Tutorial
    • Data
    • FAQ
    • Contact
  • Open Access
    • Overview
    • Development
    • FAQ
    • Contact
  • About
    • Institutions
    • Release History
    • Cookies and privacy policy

Copyright © 1998–2018.

Fivu en